Why FIH oncology trials fail before they start
A perspective on site mix, protocol assumptions, activation delays, and hidden execution risk.
Insights
Signals worth reviewing before early oncology execution.
A practical resource page for public research, oncology conference signals, and our perspective on FIH execution risk. Public Apex AI articles and official sources such as ASCO, ESMO, AACR, and SITC are available as filterable source material with original links preserved.
Featured perspectives
Start with the questions sponsors usually discover too late.
These short editorial themes give the Insights page a stable point of view even when external public-source feeds are temporarily unavailable.
Site-level activation risk vs traditional feasibility
Why averages and prestige-based KOL selection can miss the operational tails that matter.
China innovation drugs going global
How global development strategy, region selection, and trial design affect credibility outside China.
How oncology site selection should differ by mechanism
Why ADCs, bispecifics, KRAS, CAR-T, radioligands, DDR assets, and TKIs should not use the same site logic.
Article library
Public research and oncology conference signals
A unified library of public Apex AI articles and official oncology meeting sources such as ASCO, ESMO, AACR, and SITC. Filter by source, topic, or keyword; cards preserve public metadata and official source links only.
Source: All sources · Topic: Trial strategy · 2 articles · 10 per page
AI at ASCO 2026: From Topic to Tool
AI tags 220 abstracts, the largest subtrack at ASCO 2026. Most of it is applied to concrete tasks; trial matching is where it meets drug development most directly.
Open AAI articleGenitourinary Cancer at ASCO 2026 — Prostate, Bladder, Kidney
Prostate, bladder, and kidney cancer studies from ASCO 2026, organized by cancer, with trial sizes, hazard ratios, response rates, and data tables.
Open AAI article